X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (50) 50
index medicus (47) 47
female (40) 40
oncology (40) 40
aged (30) 30
middle aged (27) 27
breast cancer (26) 26
male (25) 25
adult (23) 23
chemotherapy (20) 20
aged, 80 and over (17) 17
treatment outcome (17) 17
breast neoplasms - drug therapy (14) 14
therapy (13) 13
breast neoplasms - pathology (12) 12
vinorelbine (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
antineoplastic agents - adverse effects (10) 10
cancer (10) 10
capecitabine (10) 10
prospective studies (10) 10
analysis (9) 9
efficacy (9) 9
safety (9) 9
advanced breast cancer (8) 8
cancer therapies (8) 8
hematology, oncology and palliative medicine (8) 8
metronomic chemotherapy (8) 8
antineoplastic agents - therapeutic use (7) 7
care and treatment (7) 7
clinical trials (7) 7
combination (7) 7
dermatology (7) 7
medicine & public health (7) 7
metastasis (7) 7
neuropathy (7) 7
neurotoxicity (7) 7
oxaliplatin (7) 7
paclitaxel (7) 7
patients (7) 7
risk factors (7) 7
women (7) 7
animals (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
colorectal neoplasms - drug therapy (6) 6
cyclophosphamide (6) 6
deoxycytidine - analogs & derivatives (6) 6
management (6) 6
metastases (6) 6
neoplasm metastasis (6) 6
neoplasm staging (6) 6
neurosciences (6) 6
organoplatinum compounds - adverse effects (6) 6
pharmacology & pharmacy (6) 6
surgery (6) 6
tumors (6) 6
vinblastine - analogs & derivatives (6) 6
young adult (6) 6
adjuvant therapy (5) 5
adolescent (5) 5
angiogenesis (5) 5
antimitotic agents (5) 5
antineoplastic agents (5) 5
antineoplastic agents - administration & dosage (5) 5
cancer patients (5) 5
carcinoma, non-small-cell lung - drug therapy (5) 5
chemotherapy, adjuvant (5) 5
clinical neurology (5) 5
colorectal cancer (5) 5
deoxycytidine - administration & dosage (5) 5
disease-free survival (5) 5
drug administration schedule (5) 5
drug therapy (5) 5
elderly (5) 5
everolimus (5) 5
fluorouracil (5) 5
further section (5) 5
hematology (5) 5
incidence (5) 5
italy (5) 5
italy - epidemiology (5) 5
lung neoplasms - drug therapy (5) 5
medical research (5) 5
peripheral nervous system diseases - chemically induced (5) 5
prognosis (5) 5
quality of life (5) 5
studies (5) 5
survival (5) 5
tamoxifen (5) 5
toxicity (5) 5
trial (5) 5
vinblastine - administration & dosage (5) 5
bevacizumab (4) 4
biomarkers, tumor - analysis (4) 4
drug dosages (4) 4
ecology (4) 4
erbb-2 protein (4) 4
follow-up studies (4) 4
gene expression (4) 4
genetic aspects (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1306 - 1315
Summary Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved... 
Hematology, Oncology and Palliative Medicine | TRIAL | CETUXIMAB | SURROGATE | LEUCOVORIN | ONCOLOGY | END-POINT | PROGRESSION-FREE SURVIVAL | RAS MUTATIONS | GUIDELINES | KRAS | FLUOROURACIL | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Bevacizumab - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Italy | Aged | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Cancer patients | Care and treatment | Patient outcomes | Analysis | Colorectal cancer | Leucovorin | Metastasis | Antineoplastic agents
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 1/2017, Volume 161, Issue 2, pp. 387 - 387
Journal Article
by De Placido, Sabino and Gallo, Ciro and De Laurentiis, Michelino and Bisagni, Giancarlo and Arpino, Grazia and Sarobba, Maria Giuseppa and Riccardi, Ferdinando and Russo, Antonio and Del Mastro, Lucia and Cogoni, Alessio Aligi and Cognetti, Francesco and Gori, Stefania and Foglietta, Jennifer and Frassoldati, Antonio and Amoroso, Domenico and Laudadio, Lucio and Moscetti, Luca and Montemurro, Filippo and Verusio, Claudio and Bernardo, Antonio and Lorusso, Vito and Gravina, Adriano and Moretti, Anna and Moretti, Gabriella and Lauria, Rossella and Lai, Antonella and Mocerino, Carmela and Rizzo, Sergio and Nuzzo, Antonio and Nuzzo, Francesco and Carlini, Paolo and Perrone, Francesco and Accurso, Antonello and Agostara, Biagio and Aieta, Michele and Alabiso, Oscar and Alicicco, Maria Grazia and Amadori, Dino and Amaducci, Laura and Amiconi, Gianna and Antuzzi, Giustino and Ardine, Mara and Ardizzoia, Antonio and Aversa, Caterina and Badalamenti, Giuseppe and Barni, Sandro and Basurto, Carlo and Berardi, Rossana and Bergamasco, Cinzia and Bidoli, Paolo and Bighin, Claudia and Biondi, Edoardo and Boni, Corrado and Borgonovo, Karen and Botta, Mario and Bravi, Stefano and Bruzzi, Paolo and Buono, Giuseppe and Butera, Alfredo and Caldara, Alessia and Candeloro, Giampiero and Cappelletti, Claudia and Cardalesi, Cinzia and Carfora, Elisabetta and Cariello, Anna and Carrozza, Francesco and Cartenì, Giacomo and Caruso, Michele and Casadei, Virginia and Casanova, Claudia and Castori, Luigi and Cavanna, Luigi and Cavazzini, Giovanna and Cazzaniga, Marina and Chilelli, Mario and Chiodini, Paolo and Chiorrini, Silvia and Ciardiello, Fortunato and Ciccarese, Mariangela and Cinieri, Saverio and Clerico, Mario and Coccaro, Mariarosa and Comande, Mario and Corbo, Claudia and Cortino, Giuseppina and Cusenza, Stefania and Daniele, Gennaro and D'arco, Alfonso Maria and D'auria, Giuliana and Dazzi, Claudio and De Angelis, Carmine and de Braud, Filippo and De Feo, Gianfranco and De Matteis, Andrea and De Tursi, Michele and Di Blasio, Anna and di Lucca, Giuseppe and Di Lullo, Liberato and Di Rella, Francesca and Di Renzo, Gianfranco and ... and GIM Investigators
The Lancet Oncology, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 474 - 485
Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly... 
SYSTEM | THERAPY | EFFICACY | ONCOLOGY | FOLLOW-UP | POSTMENOPAUSAL WOMEN | COMBINATION | AROMATASE INHIBITORS | Breast cancer | Product development | Tamoxifen | Analysis
Journal Article
Cancer Letters, ISSN 0304-3835, 2016, Volume 400, pp. 252 - 258
Abstract Metronomic chemotherapy refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen with no... 
Hematology, Oncology and Palliative Medicine | Oral vinorelbine | Metronomic chemotherapy | Metastatic breast cancer | CYCLOPHOSPHAMIDE | COMBINATION | INTERNATIONAL CONSENSUS GUIDELINES | CAPECITABINE | PHASE-II TRIAL | THERAPY | ONCOLOGY | ANTHRACYCLINE | PRETREATED PATIENTS | PLUS BEVACIZUMAB | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Administration, Metronomic | Breast Neoplasms - immunology | Humans | Immunologic Factors - administration & dosage | Neovascularization, Pathologic | Tumor Microenvironment | Treatment Outcome | Antineoplastic Agents - administration & dosage | Breast Neoplasms - blood supply | Breast Neoplasms - drug therapy | Dose-Response Relationship, Drug | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Animals | Antineoplastic Agents - adverse effects | Breast Neoplasms - pathology | Female | Medical research | Care and treatment | Nervous system diseases | Cancer patients | Chemotherapy | Medicine, Experimental | Breast cancer | Metastasis | Health aspects | Cancer | Lung cancer | Cytotoxicity | Dosage | Cancer therapies | ADP | Anticancer properties | Bevacizumab | Metastases | Literature reviews | Angiogenesis | Immunotherapy | Bone marrow | Inhibition | Growth factors | Drug dosages | Vascular endothelial growth factor | Regression analysis | Disease control | Survival | Studies | Side effects | Inhibitors | Blood circulation | Anthracycline | Stem cells | Documents | Drugs | Schedules | Correlation | Toxicity | Medical services | Antibodies | Clinical trials | Oncology | Biological effects | Reduction | Quality | Immune system | Immune response | Effectiveness | Tumor cells | Pharmacology | Biological activity | Cisplatin | Life span | Collagen | Response rates | Breast | Antitumor activity | Surface area | Tumors | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 02/2017, Volume 542, Issue 7642, pp. 479 - 483
B-lymphoid transcription factors, such as PAX5 and IKZF1, are critical for early B-cell development(1,2), yet lesions of the genes encoding these transcription... 
ENERGY STRESS | ACTIVATION | GENE | MACROPHAGES | MULTIDISCIPLINARY SCIENCES | ACUTE LYMPHOBLASTIC-LEUKEMIA | HEMATOPOIETIC STEM-CELLS | REGULATORY NETWORK | DIFFERENTIATION | MINIMAL RESIDUAL DISEASE | EXPRESSION | Glucocorticoids - therapeutic use | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - metabolism | Receptor, Cannabinoid, CB2 - agonists | Humans | Gene Expression Regulation, Neoplastic | Receptors, Glucocorticoid - metabolism | PAX5 Transcription Factor - deficiency | Carrier Proteins - agonists | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Chromatin Immunoprecipitation | Adenosine Triphosphate - metabolism | Cell Death | Pyruvic Acid - metabolism | Female | Ikaros Transcription Factor - metabolism | Energy Metabolism - genetics | B-Lymphocytes - metabolism | PAX5 Transcription Factor - metabolism | Protein-Serine-Threonine Kinases - metabolism | Disease Models, Animal | AMP-Activated Protein Kinases - antagonists & inhibitors | Carcinogenesis - genetics | PAX5 Transcription Factor - genetics | Mice, Transgenic | Citric Acid Cycle | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - genetics | Transcription Factors - metabolism | B-Lymphocytes - drug effects | Receptor, Cannabinoid, CB2 - metabolism | Animals | Carrier Proteins - metabolism | Sequence Analysis, RNA | Glucocorticoids - pharmacology | Glucose - metabolism | Mice | Physiological aspects | Transcription factors | B cells | Proteins | Metabolites | Rodents | Cloning | Leukemia | Glucose | Kinases | Metabolism | Gene expression | Apoptosis
Journal Article
Journal of Neurology, Neurosurgery & Psychiatry, ISSN 0022-3050, 04/2014, Volume 85, Issue 4, pp. 392 - 398
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 02/2019, Volume 83, Issue 2, pp. 301 - 318
Despite the large use of nab-paclitaxel as a treatment option in metastatic breast cancer (MBC) across different countries, no definitive data are available in... 
Expert meeting | Breast cancer | Neuropathy | Nab-paclitaxel | Weekly schedule | Antimitotic agents | Medical colleges | Care and treatment | Cancer patients | Algorithms | Metastasis | Antineoplastic agents | Effectiveness | Patients | ErbB-2 protein | Subgroups | Metastases | Literature reviews | Scientific papers | Quality | Paclitaxel | Breast | Safety | Tumors | Cancer
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2017, Volume 7, Issue 1, pp. 17638 - 9
The lack of clinically-reliable biomarkers makes impossible to predict sperm retrieval outcomes at testicular sperm extraction (TESE) in men with... 
INHIBIN-B | INFERTILE MEN | EXTRACTION | RISK-FACTORS | TESTIS | MULTIDISCIPLINARY SCIENCES | VOLUME | COMPENSATED HYPOGONADISM | SECONDARY | MATURATION | ASPIRATION | Parenchyma | Testosterone | Sperm | Surgery | Hypogonadism
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 9/2018, Volume 26, Issue 9, pp. 3143 - 3151
We aimed to verify the predictiveness of dorsal sural nerve neurophysiological monitoring in obtaining risk stratification for oxaliplatin-induced peripheral... 
Pain Medicine | Nursing | Rehabilitation Medicine | Oxaliplatin | Medicine & Public Health | Nursing Research | Risk stratification | Colorectal cancer | Oncology | Peripheral neurotoxicity |